2.00
price up icon2.04%   0.04
pre-market  プレマーケット:  2.01   0.010   +0.50%
loading
前日終値:
$1.96
開ける:
$1.96
24時間の取引高:
4.10M
Relative Volume:
0.44
時価総額:
$690.31M
収益:
$22,000
当期純損益:
$-190.89M
株価収益率:
-2.3036
EPS:
-0.8682
ネットキャッシュフロー:
$-149.63M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
-16.32%
6か月 パフォーマンス:
+62.60%
1年 パフォーマンス:
+83.49%
1日の値動き範囲:
Value
$1.955
$2.05
1週間の範囲:
Value
$1.84
$2.06
52週間の値動き範囲:
Value
$0.9842
$4.46

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
名前
Allogene Therapeutics Inc
Name
セクター
Healthcare (1106)
Name
電話
(650) 457-2700
Name
住所
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
職員
152
Name
Twitter
@AllogeneTx
Name
次回の収益日
2026-05-13
Name
最新のSEC提出書
Name
ALLO's Discussions on Twitter

Compare ALLO vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
ALLO icon
ALLO
Allogene Therapeutics Inc
2.00 676.50M 22,000 -190.89M -149.63M -0.8682
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
434.52 110.03B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
638.88 67.37B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
806.46 50.76B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
297.45 40.12B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
151.56 32.68B 742.00K -1.37B -1.07B -7.0731

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-16 アップグレード JP Morgan Underweight → Neutral
2026-04-10 再開されました Jefferies Buy
2026-01-09 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2025-10-10 ダウングレード JP Morgan Neutral → Underweight
2025-05-14 ダウングレード Citizens JMP Mkt Outperform → Mkt Perform
2025-03-14 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2024-08-08 再開されました Oppenheimer Outperform
2024-05-31 開始されました Piper Sandler Overweight
2024-01-05 ダウングレード Guggenheim Buy → Neutral
2024-01-05 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2023-12-08 開始されました Citigroup Buy
2023-06-26 再開されました Oppenheimer Outperform
2023-03-21 開始されました Bernstein Mkt Perform
2023-01-24 アップグレード JP Morgan Neutral → Overweight
2023-01-06 アップグレード Robert W. Baird Neutral → Outperform
2022-12-12 ダウングレード BofA Securities Buy → Underperform
2022-08-10 ダウングレード Raymond James Outperform → Mkt Perform
2022-07-15 アップグレード Goldman Neutral → Buy
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-28 繰り返されました B. Riley Securities Buy
2021-10-20 開始されました Cowen Outperform
2021-10-08 ダウングレード Goldman Buy → Neutral
2021-10-08 ダウングレード Stifel Buy → Hold
2021-09-23 アップグレード Raymond James Mkt Perform → Outperform
2021-06-21 再開されました Jefferies Buy
2021-05-20 アップグレード Truist Hold → Buy
2021-05-14 開始されました B. Riley Securities Buy
2021-01-26 アップグレード Stifel Hold → Buy
2020-12-10 再開されました H.C. Wainwright Buy
2020-11-24 開始されました BofA Securities Buy
2020-10-23 開始されました RBC Capital Mkts Outperform
2020-06-01 ダウングレード Raymond James Outperform → Mkt Perform
2020-05-29 繰り返されました H.C. Wainwright Buy
2020-05-19 アップグレード ROTH Capital Neutral → Buy
2020-05-15 アップグレード Guggenheim Neutral → Buy
2020-05-14 繰り返されました H.C. Wainwright Buy
2020-05-14 ダウングレード SunTrust Buy → Hold
2020-04-13 開始されました SunTrust Buy
2020-03-13 開始されました H.C. Wainwright Buy
2020-03-05 開始されました Stifel Hold
2020-02-24 開始されました Berenberg Hold
2019-12-18 開始されました JMP Securities Mkt Outperform
2019-11-04 開始されました Canaccord Genuity Buy
2019-08-09 開始されました BTIG Research Buy
2019-06-05 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Neutral
2019-05-23 開始されました Stifel Hold
2019-03-29 開始されました Piper Jaffray Overweight
すべてを表示

Allogene Therapeutics Inc (ALLO) 最新ニュース

pulisher
May 21, 2026

Allogene Therapeutics posts narrower-than-expected loss in Q1 - MSN

May 21, 2026
pulisher
May 20, 2026

Allogene Therapeutics explores ALPHA3 trial potential for allogeneic CAR T in LBCL treatment - Traders Union

May 20, 2026
pulisher
May 20, 2026

JPMorgan, Allogene Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN

May 20, 2026
pulisher
May 20, 2026

Earnings call transcript: Allogene Therapeutics Q1 2026 sees mixed results with revenue miss By Investing.com - Investing.com South Africa

May 20, 2026
pulisher
May 20, 2026

Earnings call transcript: Allogene Therapeutics Q1 2026 sees mixed results with revenue miss - Investing.com UK

May 20, 2026
pulisher
May 19, 2026

ALLO Technical Analysis | Trend, Signals & Chart Patterns | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill

May 19, 2026
pulisher
May 17, 2026

Number of shareholders of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView

May 17, 2026
pulisher
May 15, 2026

Allogene outlines cash runway into Q1 2029 while raising 2026 operating cash expense guidance to ~$165M - MSN

May 15, 2026
pulisher
May 15, 2026

Allogene Therapeutics unveils ALLO-329 with Dagger technology for next generation cell therapy - Traders Union

May 15, 2026
pulisher
May 15, 2026

Citadel affiliates, Kenneth Griffin report stakes in Allogene (ALLO) - Stock Titan

May 15, 2026
pulisher
May 15, 2026

Lynx1 amends 13G for Allogene Therapeutics (NASDAQ: ALLO) showing 0% stake - Stock Titan

May 15, 2026
pulisher
May 15, 2026

Allogene Therapeutics | SCHEDULE 13G/A: Others - Moomoo

May 15, 2026
pulisher
May 15, 2026

A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $7 to $14 - Moomoo

May 15, 2026
pulisher
May 15, 2026

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2026 Earnings Call Transcript - Insider Monkey

May 15, 2026
pulisher
May 15, 2026

Piper Sandler Sticks to Their Buy Rating for Allogene Therapeutics (ALLO) - The Globe and Mail

May 15, 2026
pulisher
May 15, 2026

Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO) - The Globe and Mail

May 15, 2026
pulisher
May 14, 2026

Analysts’ Top Healthcare Picks: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN) - The Globe and Mail

May 14, 2026
pulisher
May 14, 2026

A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $9 to $14 - Moomoo

May 14, 2026
pulisher
May 14, 2026

Allogene Therapeutics (NASDAQ:ALLO) Shares Down 7.7%Here's What Happened - MarketBeat

May 14, 2026
pulisher
May 14, 2026

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1 - The Globe and Mail

May 14, 2026
pulisher
May 14, 2026

Oppenheimer Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $7 - Moomoo

May 14, 2026
pulisher
May 14, 2026

RBC Capital Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $9 - Moomoo

May 14, 2026
pulisher
May 14, 2026

Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $10 - Moomoo

May 14, 2026
pulisher
May 14, 2026

Transcript : Allogene Therapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 - marketscreener.com

May 14, 2026
pulisher
May 14, 2026

Allogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Highlights: Promising Trial Results and Financial Strength - GuruFocus

May 14, 2026
pulisher
May 13, 2026

TD Cowen Maintains Allogene Therapeutics(ALLO.US) With Buy Rating - Moomoo

May 13, 2026
pulisher
May 13, 2026

ALLO Adjusts 2026 Operating Expense Guidance - GuruFocus

May 13, 2026
pulisher
May 13, 2026

Allogene Therapeutics Q1 Earnings Call Highlights - MarketBeat

May 13, 2026
pulisher
May 13, 2026

Allogene Therapeutics ends China cell therapy deal with Overland - 1470 & 100.3 WMBD

May 13, 2026
pulisher
May 13, 2026

Allogene Therapeutics (NASDAQ: ALLO) Belldegrun reports 13.47M-share stake - Stock Titan

May 13, 2026
pulisher
May 13, 2026

ALLO Secures Funding, Extends Cash Runway to 2029 - GuruFocus

May 13, 2026
pulisher
May 13, 2026

Allogene (ALLO) Q1 2026 Earnings Transcript - The Globe and Mail

May 13, 2026
pulisher
May 13, 2026

ALLO: Interim data show robust efficacy and safety for cema-cel and early promise for ALLO-329, with solid financials - TradingView

May 13, 2026
pulisher
May 13, 2026

Allogene Therapeutics Q1 Net Loss Narrows - Moomoo

May 13, 2026
pulisher
May 13, 2026

Allogene Therapeutics Q1 2026 Earnings Call Transcript - Benzinga

May 13, 2026
pulisher
May 13, 2026

Earnings call transcript: Allogene Therapeutics beats EPS expectations in Q1 2026 - Investing.com

May 13, 2026
pulisher
May 13, 2026

Allogene Therapeutics releases Q1 corporate update with focus on allogeneic cell therapy progress - Traders Union

May 13, 2026
pulisher
May 13, 2026

Allogene Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2026
pulisher
May 13, 2026

Allogene Highlights ALPHA3 Data and Extended Cash Runway - TipRanks

May 13, 2026
pulisher
May 13, 2026

Is Allogene Therapeutics (ALLO) Undervalued After Q1 2026? EPS - GuruFocus

May 13, 2026
pulisher
May 13, 2026

Allogene Therapeutics (ALLO) insider holdings: Dr. Chang 4.9% ownership disclosed - Stock Titan

May 13, 2026
pulisher
May 13, 2026

Allogene TherapeuticsEnters Termination Agreement With Overland Therapeutics On May 12, 2026SEC Filing - TradingView

May 13, 2026
pulisher
May 13, 2026

Earnings Flash (ALLO) Allogene Therapeutics Posts Q1 Loss $0.18, vs. FactSet Est of $0.19 Loss - marketscreener.com

May 13, 2026
pulisher
May 13, 2026

Allogene Therapeutics: Q1 Earnings Snapshot - Barchart.com

May 13, 2026
pulisher
May 13, 2026

Allogene (NASDAQ: ALLO) extends cash runway to 2029 as CAR T trials advance - Stock Titan

May 13, 2026
pulisher
May 13, 2026

Allogene Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 13, 2026
pulisher
May 13, 2026

Allogene (NASDAQ: ALLO) posts Q1 2026 loss, updates ALPHA3 data and cash runway - Stock Titan

May 13, 2026
pulisher
May 13, 2026

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update - GlobeNewswire

May 13, 2026
pulisher
May 13, 2026

More on Allogene Therapeutics - MSN

May 13, 2026
pulisher
May 13, 2026

Allogene Therapeutics Q1 2026 earnings preview - MSN

May 13, 2026
pulisher
May 13, 2026

Allogene Therapeutics and Overland End Greater China CAR T License; No Termination Payments - TradingView

May 13, 2026

Allogene Therapeutics Inc (ALLO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$29.96
price down icon 2.98%
$106.24
price down icon 3.00%
$92.14
price up icon 1.33%
$54.50
price up icon 1.77%
ONC ONC
$310.25
price up icon 0.20%
$151.56
price down icon 1.41%
大文字化:     |  ボリューム (24 時間):